AbbVie Inc. $ABBV Position Increased by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 10.7% during the third quarter, Holdings Channel reports. The firm owned 132,821 shares of the company’s stock after acquiring an additional 12,862 shares during the quarter. Farther Finance Advisors LLC’s holdings in AbbVie were worth $34,745,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Burk Holdings LLC purchased a new stake in shares of AbbVie in the 2nd quarter valued at $30,000. Marquette Asset Management LLC lifted its stake in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares in the last quarter. Abound Financial LLC purchased a new position in AbbVie during the 4th quarter valued at about $32,000. Principia Wealth Advisory LLC boosted its holdings in AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC acquired a new position in AbbVie in the 1st quarter valued at about $34,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. BMO Capital Markets increased their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. UBS Group restated a “neutral” rating on shares of AbbVie in a report on Tuesday. Royal Bank Of Canada upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Finally, Argus raised their price target on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $276.64.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

AbbVie Stock Performance

Shares of ABBV traded up $0.84 during midday trading on Thursday, hitting $272.20. The company had a trading volume of 5,492,274 shares, compared to its average volume of 6,424,160. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94. The firm has a market capitalization of $480.92 billion, a P/E ratio of 76.89, a P/E/G ratio of 1.22 and a beta of 0.24. The company’s 50-day simple moving average is $258.27 and its 200-day simple moving average is $235.87.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.